European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder
Retrieved on:
Thursday, August 26, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Private Securities Litigation Reform Act, Pharming, Annual report, Regulatory affairs, CDKL5, EMA, Epilepsy, CHMP, CDD, Ganaxolone, Marigold, Therapy, Genetic disorder, Orion, Growth, European Directive on Traditional Herbal Medicinal Products, U.S. Securities and Exchange Commission, MAA, Seizure, European Medicines Agency, Food, Somnolence, Committee, Committee for Medicinal Products for Human Use, Marketing, NDA, Forward-looking statement, GABAA, Review, Mutation, Public health, X chromosome, Clinical trial, Medication, Senior, Safety, Adult, Patient, Marinus, FDA, Brain, COVID-19, Orion Corporation, Security (finance), Form 10-K, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Vaccine
If approved, our collaboration with Orion Corporation supports our efforts to bring ganaxolone to European markets as quickly as possible for CDD patients who may benefit.
Key Points:
- If approved, our collaboration with Orion Corporation supports our efforts to bring ganaxolone to European markets as quickly as possible for CDD patients who may benefit.
- Accelerated assessment is granted by the CHMP when a medicinal product is expected to be of major public health interest and therapeutic innovation.
- CDKL5 deficiency disorder (CDD) is a serious and rare genetic disorder that is caused by a mutation of the cyclindependent kinaselike 5 (CDKL5) gene, located on the X chromosome.
- Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.